Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-24 @ 11:33 PM
NCT ID:
NCT00040456
Eligibility Criteria:
Inclusion criteria:
This protocol is open to male and female patients of all races with a diagnosis of severe sickle hemoglobinopathy providing they also satisfy the following eligibility criteria:
* Adult and pediatric patients with Hb SC disease who are able to swallow the Mg pidolate preparation and who have had at least one prior painful crisis.
Exclusion Criteria:
* Patients transfused within 90 days of study entry,
* Patients with elevated (\>1.5 times upper limit of normal for age) BUN, creatinine, or liver function tests \> 3 times the upper limit of normal for age,
* Patients who take a magnesium-containing medication (Mylanta, Maalox, etc.) on a regular (i.e., more than 2 days per week) basis.
* Patients with progressive neuromuscular disease or patients who are treated with a calcium channel blocker.
* Pregnancy
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00040456
Study Brief:
Protocol Section:
NCT00040456